Objective: To analyze the expression of RHOJ in patients with gastric cancer and its relationship with clinicopathological features, prognosis and immune infiltration of tumor microenvironment based on database, and to explore the related mechanism. Methods: By searching UALCAN and HPA databases, we investigated the differential expression of RHOJ in gastric cancer and normal tissues, and the subcellular expression of RHOJ. The TCGA database and GEO database were searched. RNA-Seq data and clinical baseline data of 415, 76 and 434 cases of gastric cancer tissues were downloaded from Omnibus database GSE84426 and GSE84437, respectively. The relationship between RHOJ expression and clinicopathological features in TCGA and GEO databases was analyzed. The correlation between RHOJ expression in TCGA database and clinical baseline data and prognosis was analyzed by Cox regression analysis. KM-plotter database was used to analyze the relationship between RHOJ expression and prognosis of gastric cancer patients, and the survival curve and immune treatment-related receiver operating characteristic(ROC) curve were drawn. TISIDB database was searched to evaluate the relationship between RHOJ expression and immune invasion of gastric cancer microenvironment. Proteins associated with RHOJ were analyzed through STRING database. Gene ontology(GO) function annotation and KEGG pathway enrichment analyses were also conducted. Results: Compared with the normal control group, RHOJ had a low expression in gastric cancer tissues, which was related to immune invasion of gastric cancer tumors and was helpful to evaluate the efficacy of immunotherapy for gastric cancer. The low expression of RHOJ in patients with gastric cancer was an indicator of good prognosis. Conclusion: RHOJ can be used as a biological marker affecting the prognosis of patients with gastric cancer, and has a good diagnostic value. |
[1] VAN CUTSEM E,SAGAERT X,TOPAL B,et al.Gastric cancer[J].Lancet,2016,388(10060):2654-2664.
[2] RUGGE M.Gastric cancer risk:between genetics and lifestyle[J].Lancet Oncol,2020,21(10):1258-1260.
[3] RAY K.New markers and models of premalignancy and the early development of gastric cancer[J].Nat Rev Gastroenterol Hepatol,2020,17(4):193.
[4] 陈怡,朱艳丽,李云凤,等.胃癌化疗及靶向治疗药物的研究进展[J].广东化工,2023,50(13):92-93,106.
[5] EL MASRI R,DELON J.RHO GTPases:from new partners to complex immune syndromes[J].Nat Rev Immunol,2021,21(8):499-513.
[6] LESZCZYNSKA K,KAUR S,WILSON E,et al.The role of RhoJ in endothelial cell biology and angiogenesis[J].Biochem Soc Trans,2011,39(6):1606-1611.
[7] WILSON E,LESZCZYNSKA K,POULTER N S,et al.RhoJ interacts with the GIT-PIX complex and regulates focal adhesion disassembly[J].J Cell Sci,2014,127(14):3039-3051.
[8] DEBAUGNIES M,RODRíGUEZ-ACEBES S,BLONDEAU J,et al.RHOJ controls EMT-associated resistance to chemotherapy[J].Nature,2023,616(7955):168-175.
[9] ILIC M,ILIC I.Epidemiology of stomach cancer[J].World J Gastroenterol,2022,28(12):1187-1203.
[10] JOSHI S S,BADGWELL B D.Current treatment and recent progress in gastric cancer[J].CA Cancer J Clin,2021,71(3):264-279.
[11] XU W,YANG Z,LU N.Molecular targeted therapy for the treatment of gastric cancer[J].J Exp Clin Cancer Res,2016,35(1):1.
[12] 彭瑶,杨公利,钟慕晓,等.基于间充质干细胞的胃癌基因治疗研究[J].胃肠病学和肝病学杂志,2015,24(2):217-219.
[13] SHI T T,LI G,XIAO H T.The role of RhoJ in endothelial cell biology and tumor pathology[J].Biomed Res Int,2016,2016:6386412.
[14] HO H,SOTO HOPKIN A,KAPADIA R,et al.RhoJ modulates melanoma invasion by altering actin cytoskeletal dynamics[J].Pigment Cell Melanoma Res,2013,26(2):218-225.
[15] 戴荣源.RHOJ控制上皮-间质转化相关的化疗耐药[J].中国临床药理学杂志,2023,39(9):1266.
[16] 徐伟,王舟,陈晓,等.早发性胃癌早期诊断、预防及治疗的研究进展[J].东南大学学报(医学版),2023,42(4):637-642. |